在微观多炎中降低葡萄糖皮质体剂量的安全性:一个多中心REVEAL队列研究
Hirofumi Miyake1, Takuya Kotani2, Shogo Matsuda2
1Department of General Internal Medicine, Tenri Hospital, Tenri, Japan.
Modern rheumatology
|June 9, 2025
概括
在微观多管炎患者中,将葡萄糖皮质类药物 (GC) 减少到6个月后每天10毫克,并没有增加死亡率或复发风险. 这表明,在管理这种自身免疫性疾病时,GC缩小是一个可行的目标.
科学领域:
- 类风湿病学 类风湿病学
- 临床免疫学临床免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 微观多炎 (MPA) 是一种罕见的自身免疫性血管炎,通常用葡萄糖皮质类药物 (GCs) 治疗.
- 长期使用GC与重大不良事件有关.
- 优化GC缩小策略对于改善MPA患者的治疗结果至关重要.
研究的目的:
- 评估在被诊断患有微观多炎 (MPA) 的患者中减少葡萄糖皮质体 (GCs) 的安全性和有效性.
- 为了确定6个月的GC剂量目标≤10毫克/天的普雷迪尼索隆等效是否与不良结果相关.
主要方法:
- 从REVEAL队列 (2005-2023) 中对223名MPA患者进行了回顾性分析.
- 患者根据6个月的GC剂量 (≤10vs>10毫克/天) 分层.
- 重叠加权衡平衡基线特征; 考克斯模型评估了10年的结果; 物流回归确定了GC剂量的预测因素.
主要成果:
- 在6个月后将GCs降低到≤10毫克/天,没有增加任何原因死亡率,感染相关死亡率或住院感染的风险.
- 在较低的GC剂量下,没有观察到所有复发或重大复发的显著增加.
- 从2020年开始的治疗与在6个月内达到≤10毫克/天GC剂量相关 (或5.54).
结论:
- 在MPA患者中,6个月GC目标≤10毫克/天似乎是安全的,不会增加死亡率或复发风险.
- 虽然这是一个可行的中间目标,但为了最大限度地降低感染风险,可能需要更积极的GC降低.
- 个性化GC逐渐和密切的患者监测仍然是有效管理MPA的关键.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
211
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
211
Renal Failure: Dose Adjustments
439
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
439
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
229
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
229


